Targeting TGF-β Signaling for Therapeutic Gain

Area of Science:

• Molecular Biology
• Cell Biology
• Oncology

Background:

• Transforming growth factor-beta (TGF-β) ligands are multifunctional signaling molecules with critical roles in maintaining tissue homeostasis.
• Dysregulated TGF-β signaling, characterized by ligand overexpression, is implicated in the progression of various diseases, notably fibrosis and cancer.
• TGF-β exerts its effects through heterotetrameric receptor complexes, with signaling outcomes being highly context-dependent.

Purpose of the Study:

• To review the fundamental aspects of TGF-β signaling pathways and their biological relevance in oncology.
• To summarize current pharmacological strategies aimed at inhibiting TGF-β signaling.
• To provide an update on preclinical and clinical investigations of TGF-β blockade in solid tumors.

Main Methods:

• Literature review of TGF-β signaling mechanisms.
• Analysis of pharmacological agents targeting TGF-β pathways.
• Compilation of data from preclinical and clinical trials involving TGF-β blockade in cancer.

Main Results:

• TGF-β signaling is essential for normal tissue function but contributes to cancer development and progression when dysregulated.
• Various strategies for pharmacological blockade of TGF-β signaling have been developed.
• Preclinical and clinical studies are evaluating the efficacy of TGF-β blockade across diverse solid tumor types.

Conclusions:

• Targeting TGF-β signaling represents a promising therapeutic avenue for various cancers.
• Understanding the context-dependent nature of TGF-β signaling is crucial for effective therapeutic intervention.
• Ongoing clinical trials will elucidate the full potential of TGF-β blockade in cancer treatment.